CVS Health Names David Joyner Chair of the Board of Directors
CVS Health (NYSE: CVS) announced that its Board elected President and CEO David Joyner as Chair of the Board, effective January 1, 2026. Michael Mahoney will remain the Board's Lead Independent Director, and Roger Farah will continue to serve on the Board after stepping down from Executive Chair.
Joyner was named President and CEO in October 2024 and the Board cited his nearly 40 years of industry experience and a year of operational, financial and cultural improvements. The company noted its workforce of more than 300,000 colleagues and said the combined Chair and CEO structure aims to support execution of long-term strategy and stockholder value.
CVS Health (NYSE: CVS) ha annunciato che il suo Consiglio ha eletto David Joyner, presidente e CEO, come Presidente del Consiglio, con effetto dal 1 gennaio 2026. Michael Mahoney rimarrà Lead Independent Director del Consiglio, e Roger Farah continuerà a far parte del Consiglio dopo essersi dimesso dalla carica di Presidente Esecutivo.
Joyner è stato nominato presidente e CEO nell'ottobre 2024, e il Consiglio ha citato i suoi quasi 40 anni di esperienza nel settore e un anno di miglioramenti operativi, finanziari e culturali. L'azienda ha segnalato una forza lavoro di più di 300.000 colleghi e ha detto che la struttura combinata Presidente e CEO mira a supportare l'esecuzione della strategia a lungo termine e il valore per gli azionisti.
CVS Health (NYSE: CVS) anunció que su Junta Directiva eligió al David Joyner, presidente y CEO, como Presidente de la Junta, con efecto a partir del 1 de enero de 2026. Michael Mahoney permanecerá como Lead Independent Director de la Junta, y Roger Farah continuará formando parte de la Junta tras dimitir como Presidente Ejecutivo.
Joyner fue nombrado presidente y CEO en octubre de 2024, y la Junta citó sus casi 40 años de experiencia en la industria y un año de mejoras operativas, financieras y culturales. La empresa señaló una plantilla de más de 300.000 colegas y dijo que la estructura combinada de Presidente y CEO tiene como objetivo apoyar la ejecución de la estrategia a largo plazo y el valor para los accionistas.
CVS Health (NYSE: CVS) 이사회는 회장 겸 CEO David Joyner를 이사회 의장으로 선출했고, 시효는 2026년 1월 1일부터 시행됩니다. Michael Mahoney는 이사회 Lead Independent Director로 남고, Roger Farah는 Exec Chair에서 물러난 뒤 이사회에서 계속 재직합니다.
Joyner는 2024년 10월에 사장 겸 CEO로 임명되었으며, 이사회는 그의 거의 40년에 달하는 업계 경험과 1년간의 운영, 재무 및 문화 개선을 언급했습니다. 회사는 30만 명이 넘는 동료로 구성된 직원을 언급했고, 의장과 CEO를 겸하는 구조가 장기 전략의 실행과 주주 가치를 지원하는 것을 목표로 한다고 말했습니다.
CVS Health (NYSE: CVS) a annoncé que son Conseil a élu David Joyner, président et PDG, comme Président du Conseil, à compter du 1er janvier 2026. Michael Mahoney restera Lead Independent Director du Conseil, et Roger Farah continuera à siéger au Conseil après avoir cédé le poste de Président exécutif.
Joyner a été nommé président et PDG en octobre 2024, et le Conseil a souligné ses près de 40 années d'expérience dans l'industrie et une année d'améliorations opérationnelles, financières et culturelles. L'entreprise a noté une force de travail de plus de 300 000 collègues et a déclaré que la structure associant Président et PDG vise à soutenir l'exécution de la stratégie à long terme et la valeur pour les actionnaires.
CVS Health (NYSE: CVS) gab bekannt, dass sein Vorstand David Joyner, Präsident und CEO, zum Vorsitzenden des Vorstands gewählt wurde, gültig ab dem 1. Januar 2026. Michael Mahoney bleibt Lead Independent Director des Vorstands, und Roger Farah wird weiterhin dem Vorstand angehören, nachdem er den Posten des Executive Chair niedergelegt hat.
Joyner wurde im Oktober 2024 zum Präsidenten und CEO ernannt, und der Vorstand verwies auf seine fast 40 Jahre Branchenerfahrung sowie ein Jahr operativer, finanzieller und kultureller Verbesserungen. Das Unternehmen hob seine Belegschaft von mehr als 300.000 Kolleginnen und Kollegen hervor und sagte, dass die kombinierte Chair- und CEO-Struktur darauf abzielt, die Umsetzung der langfristigen Strategie und den Wert für Aktionäre zu unterstützen.
CVS Health (NYSE: CVS) أعلنت أن مجلسها اختار الرئيس والمدير التنفيذي David Joyner كـ رئيس مجلس الإدارة، اعتباراً من 1 يناير 2026. سيبقى Michael Mahoney المدير المنفرد المؤسس Lead Independent Director في المجلس، وسيواصل Roger Farah خدمة المجلس بعد التخلي عن منصب رئيس مجلس الإدارة التنفيذي.
تم تسمية Joyner رئيساً ونائباً للرئيس التنفيذي في أكتوبر 2024 وذكر المجلس خبرته التي تقترب من 40 عاماً في الصناعة وعلى مدى عام من التحسينات التشغيلية والمالية والثقافية. أشارت الشركة إلى وجود أكثر من 300,000 زميل في القوة العاملة وقالت إن هيكلية الجمعية بين رئيس المجلس والمدير التنفيذي تهدف إلى دعم تنفيذ الاستراتيجية طويلة الأجل وقيمة المساهمين.
- David Joyner elected Chair effective January 1, 2026
- Joyner named CEO in October 2024
- Company employs more than 300,000 colleagues
- Board approved combined Chair and CEO roles, concentrating leadership
Insights
CVS consolidates CEO and Chair roles under David Joyner, a governance shift that changes oversight dynamics.
CVS Health is moving to a combined Chair/CEO structure effective
The main dependency is independent oversight: retaining a Lead Independent Director mitigates, but does not eliminate, the concentrated authority that comes with combining Chair and CEO. This structure can speed decision-making and strategic execution, but it also raises standard governance questions about board independence and checks on management.
Watch near-term indicators such as any updates to board committee leadership, the Lead Independent Director’s stated responsibilities, and governance disclosures around director independence over the next 6-12 months; monitor how the board documents oversight of strategy and risk after
Joyner was named President and CEO of CVS Health in October 2024, and has led significant operational, financial and cultural improvements in the Company's performance over the past year. In recognition of his leadership, nearly 40 years of experience in the health care industry, and the Company's future growth opportunities, the Board determined Joyner should also serve as Chair of the Board.
"David has sparked a renewed focus and energy for CVS Health in our commitment to be the most trusted health care company in America," said Farah. "The Board believes in the leadership that David and his team have demonstrated. We have determined that now is the right time to have one leader with deep industry experience in the combined Chair and CEO roles, and that this structure will provide the best opportunity to execute on our long-term strategy and create stockholder value. We are bullish on the future of CVS Health in delivering a simpler care experience and better health across our country."
"I am honored to lead our more than 300,000 colleagues who are resolutely driven to simplify health care, one person, one family, and one community at a time," said Joyner. "Our collection of businesses delivers best what people want most: a coordinated and connected approach to health care that is accessible, affordable and available on your terms. We are confident in our future because of the commitment of our colleagues to care for their friends, families and neighbors.
"I am grateful to Roger for his support and guidance as I took on the role of President and CEO. His ongoing counsel is valuable to me, the Board and our leadership team, as we continue to navigate a dynamic environment and drive our strategy."
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of September 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com
Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-names-david-joyner-chair-of-the-board-of-directors-302622284.html
SOURCE CVS Health
FAQ
When does David Joyner become Chair of CVS (CVS)?
Will CVS keep an independent board leader after Joyner becomes Chair (CVS)?
What changed in CVS leadership when Joyner became CEO and Chair (CVS)?
Is Roger Farah leaving the CVS board after the Chair change (CVS)?
What reasons did CVS give for making Joyner Chair (CVS)?
